Enliven Therapeutics
ELVN
26 hedge funds and large institutions have $7.76M invested in Enliven Therapeutics in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 8 closing their positions.
3.13% less ownership
Funds ownership: 13.25% → 10.12% (-3.1%)
16% less funds holding
Funds holding: 31 → 26 (-5)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
64% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 11
70% less capital invested
Capital invested by funds: $26.2M → $7.76M (-$18.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
+$96.1K |
| 2 |
Goldman Sachs
New York
|
+$47.7K |
| 3 |
Rockefeller Capital Management
New York
|
+$22K |
| 4 |
BlackRock
New York
|
+$19K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$2.81M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$696K |
| 3 |
PVI
Pura Vida Investments
New York
|
-$370K |
| 4 |
LCM
Laurion Capital Management
New York
|
-$292K |
| 5 |
Two Sigma Investments
New York
|
-$153K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PVI
26
Pura Vida Investments
New York
| – | -$370K | -49,159 | Closed |
|
|
LCM
27
Laurion Capital Management
New York
| – | -$292K | -38,796 | Closed |
|
|
PCM
28
Prelude Capital Management
New York
| – | -$37K | -4,886 | Closed |
|
29
Millennium Management
New York
| – | -$19K | -2,577 | Closed |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| – | -$2K | -208 | Closed |
|
31
Simplex Trading
Chicago,
Illinois
| – | -$411 | -84 | Closed |
|
32
Wells Fargo
San Francisco,
California
| – | +$5 | +1 | +5% |
|
ELVN Hedge Fund Activity: Q2 2022 in Review
26 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q2 2022, worth a combined $7.76M — down 70% from $26.2M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ELVN and 3 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 4 added.
The largest buyer was Marquette Asset Management, opening a new position worth an estimated $96.1K. The largest seller was NEA Management Company, cutting an estimated $2.81M.
- 26 institutional investors held Enliven Therapeutics (ELVN) as of Q2 2022, down from 31 in Q1 2022.
- Funds reported $7.76M of Enliven Therapeutics stock for Q2 2022, down 70% quarter-over-quarter.
- 3 funds opened new Enliven Therapeutics positions in Q2 2022 and 8 closed out, a net change of -5 holders.
- The largest Enliven Therapeutics buyer in Q2 2022 was Marquette Asset Management, an estimated $96.1K added.
- The largest Enliven Therapeutics seller in Q2 2022 was NEA Management Company, an estimated $2.81M sold.
Based on aggregated 13F filings for Q2 2022.